Background
Methods
Patient population
Blood pressure measurements
Identification of hypertension
Methods of analysis
Statistical analysis
Results
Characteristics of the study subjects
Hypertensive crisis by age group
Age (years) | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|
<1 (n = 7) | 1–6 (n = 5) | 7–12 (n = 19) | 13–18 (n = 24) | |||||||
Variables | N | % | N | % | N | % | N | % | P-value1
| P-value2
|
Gender
| ||||||||||
Female | 0 | 0.0 | 3 | 60.0 | 4 | 21.1 | 2 | 8.3 | 0.037 | 0.517 |
Male | 7 | 100.0 | 2 | 40.0 | 15 | 78.9 | 22 | 91.7 | ||
Family history | 0 | 0.0 | 0 | 0.0 | 2 | 10.5 | 6 | 25.0 | 0.362 | 0.049 |
Blood Pressure
| ||||||||||
SBP > 99th percentile +5 | 7 | 100.0 | 4 | 80.0 | 19 | 100.0 | 24 | 100.0 | 0.091 | 0.282 |
DBP > 99th percentile +5 | 6 | 85.7 | 3 | 60.0 | 14 | 73.7 | 19 | 79.2 | 0.779 | 0.955 |
Stage of hypertension | ||||||||||
Stage 1 | 0 | 0.0 | 1 | 20.0 | 0 | 0.0 | 0 | 0.0 | 0.108 | 0.313 |
Stage 2 | 7 | 100.0 | 4 | 80.0 | 19 | 100.0 | 24 | 100.0 | ||
Clinical presentations
| ||||||||||
Altered Consciousness | 2 | 28.6 | 2 | 40.0 | 2 | 10.5 | 3 | 12.5 | 0.068 | 0.372 |
Headache | 0 | 0.0 | 3 | 60.0 | 13 | 68.4 | 14 | 58.3 | 0.085 | 0.054 |
Nausea/Vomiting | 2 | 28.6 | 2 | 40.0 | 8 | 42.1 | 8 | 33.3 | 0.922 | 0.960 |
Visual symptoms | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 2 | 8.3 | 0.693 | 0.201 |
Seizure | 1 | 14.3 | 2 | 40.0 | 1 | 5.3 | 2 | 8.3 | 0.142 | 0.282 |
Dizzy | 2 | 28.6 | 0 | 0.0 | 11 | 57.9 | 12 | 50.0 | 0.094 | 0.130 |
Chest pain | 0 | 0.0 | 1 | 20.0 | 8 | 42.1 | 7 | 29.2 | 0.195 | 0.187 |
End-organ damage | 2 | 28.6 | 2 | 40.0 | 3 | 15.8 | 2 | 8.3 | 0.178 | 0.086 |
Reversibility
| 3 | 42.9 | 3 | 60.0 | 9 | 47.4 | 13 | 54.2 | 0.931 | 0.701 |
Anti-HTN drugs
| 2 | 28.6 | 2 | 40.0 | 10 | 52.6 | 16 | 66.7 | 0.285 | 0.054 |
Etiology
| ||||||||||
Essential HTN | 0 | 0.0 | 1 | 20.0 | 8 | 42.1 | 15 | 62.5 | 0.008 | 0.001 |
Renal disease | 3 | 42.9 | 1 | 20.0 | 6 | 31.6 | 4 | 16.7 | 0.423 | 0.166 |
CNS | 2 | 28.6 | 1 | 20.0 | 0 | 0.0 | 1 | 4.1 | 0.202 | 0.120 |
Endocrine/metabolic | 1 | 14.3 | 1 | 20.0 | 3 | 15.8 | 4 | 16.7 | 0.952 | 0.358 |
CV | 1 | 14.3 | 0 | 0.0 | 1 | 5.3 | 0 | 0.0 | 0.252 | 0.117 |
Oncology | 0 | 0.0 | 1 | 25.0 | 1 | 5.3 | 0 | 0.0 | 0.092 | 0.389 |
Recurrent episode
| 4 | 57.1 | 1 | 20.0 | 5 | 26.3 | 6 | 25.0 | 0.440 | 0.196 |
Severity
| ||||||||||
Urgency | 5 | 71.4 | 3 | 60.0 | 16 | 84.2 | 22 | 91.7 | 0.178 | 0.086 |
Emergency | 2 | 28.6 | 2 | 40.0 | 3 | 15.8 | 2 | 8.3 | ||
Hospitalization
| ||||||||||
Ward | 3 | 42.9 | 4 | 80.0 | 8 | 42.1 | 9 | 37.5 | 0.425 | 0.398 |
ICU | 0 | 0.0 | 1 | 20.0 | 3 | 15.8 | 3 | 12.5 | 0.271 | 0.886 |
POU | 4 | 57.1 | 0 | 0.0 | 8 | 42.1 | 12 | 50.0 | 1.000 | 0.565 |
Age | 1–6 (n = 3)a
| 7–12 (n = 13)b
| 13–18 (n = 18)c
| P-value | Post hoc tests |
---|---|---|---|---|---|
Mean ± SD | Mean ± SD | Mean ± SD | |||
BW | 27.67 ± 20.43 | 53.35 ± 28.19 | 83.64 ± 33.27 | 0.005 | a,b < c |
Height | 103.00 ± 15.72 | 144.66 ± 10.38 | 167.95 ± 9.58 | <0.001 | a < b < c |
Height Z-Score | −8.85 ± 2.91 | −3.43 ± 1.15 | −0.70 ± 1.24 | <0.001 | a < b < c |
BMI | 24.30 ± 12.95 | 24.88 ± 12.60 | 29.05 ± 9.08 | 0.522 | |
BMI Z-score | 1.52 ± 1.68 | 1.13 ± 1.49 | 3.07 ± 6.96 | 0.587 | |
BMI Percentile | 81.33 ± 20.74 | 75.54 ± 31.11 | 84.56 ± 25.93 | 0.675 | |
SBP | 189.67 ± 36.91 | 158.38 ± 25.09 | 164.22 ± 23.84 | 0.174 | |
DBP | 136.00 ± 38.16 | 93.54 ± 19.98 | 104.61 ± 19.03 | 0.013 | a > b |
Expected SBP | 103.80 ± 16.23 | 95.17 ± 4.12 | 109.91 ± 5.11 | <0.001 | b < c |
Expected DBP | 76.78 ± 22.76 | 54.46 ± 3.42 | 62.32 ± 3.76 | <0.001 | a > c > b |
SBP Z-score | 8.10 ± 4.15 | 5.93 ± 2.34 | 5.08 ± 2.17 | 0.135 | |
DBP Z-score | 5.22 ± 5.26 | 3.41 ± 1.74 | 3.68 ± 1.75 | 0.432 |
Patients with hypertensive encephalopathy
Case 1 | Case 2 | Case 3 | Case 4 | Case 5 | |
---|---|---|---|---|---|
Gender (F/M) | M | M | M | M | M |
Age (year) | 9 | 12 | 13 | 5 | 14 |
Weight (kg) | 24 | 39 | 68 | 19 | 35 |
Height (cm) | 134 | 158 | 110 | ||
Family history | no | no | no | no | no |
Arrival BP | 166/130 | 176/86 | 220/128 | 231/172 | 148/109 |
Hypertension stage | stage 2 | stage 2 | stage 2 | stage 2 | stage 2 |
SBP > 99th percentile + 5 | 33(25.3%) | 42(31.4%) | 82(59.4%) | 106(84.8%) | 3(2%) |
DBP > 99th percentile + 5 | 38(41.3%) | 34(36.1%) | 86(101%) | 12(11%) | |
clinical manifestations | |||||
Consciousness change | Coma | Coma | Coma | Drowsy | Disturbance |
Headache | + | 0 | + | + | + |
Nausea/Vomiting | 0 | 0 | + | + | + |
Visual symptoms | 0 | 0 | + | 0 | 0 |
Seizure | 0 | 0 | 0 | + | + |
Dizzy | 0 | 0 | 0 | 0 | + |
Chest tightness | 0 | 0 | 0 | 0 | 0 |
Drug for anti-HTN | Labetalol, Furosemide | Labetalol | Nifedipine, Labetalol | Nifedipine | captopril / amlodipine |
Underlying causes | oncology Pheochromocytoma | 0 | 0 | oncology Paraganglioneuroma | Renal disease |
Recurrent episode (times) | 0 | 0 | 0 | 3 | >5 |
CSF data | 0 | 0 | 0 | 0 | normal |
EEG finding | 0 | 0 | normal | 0 | normal |
Hospitalization duration (days) (ward/ICU/POU) | 9(4/5/0) | 11(5/6/0) | 5(3/2/0) | 7(7/0/0) | 6(6/0/0) |